[AVBC 2025] Impact of a pharmacist-run dupilumab monitoring service
Care Process & Redesign
Appropriate & Value-based Care Conference
National Healthcare Group
17 November 2025
To evaluate the clinical outcomes, patient satisfaction, and cost savings of a pharmacist-led dupilumab monitoring service. The pharmacist-run dupilumab monitoring service demonstrated satisfactory clinical outcomes and high patient satisfaction at a lower.
Year Submitted: 2025
Published Date: 17 November 2025
Tags: Care Process ＆ Redesign, Productivity, Cost Saving, Value Based Care, Patient Satisfaction, Quality Improvement, Workflow Redesign, Clinical Practice Improvement
About this Content
Aims
To evaluate the clinical outcomes, patient satisfaction, and cost savings of a pharmacist-led dupilumab monitoring service.
Background
Dupilumab is an effective and well-tolerated biologic for moderate-severe atopic dermatitis (AD). Common adverse reactions in the Asian population include ocular symptoms and head and neck dermatitis. The Pharmacist Eczema Clinic (PEC) implemented a dupilumab monitoring service to review patients for potential adverse reactions 2 to 4 weeks after initiation.
Methods
A retrospective chart review was conducted at the National Skin Centre on patients who started on dupilumab between 31 July 2020 and 4 Jan 2023. Outcomes of those reviewed by PEC were compared with those seen by dermatologists.
Results
The pharmacist-run dupilumab monitoring service demonstrated satisfactory clinical outcomes and high patient satisfaction at a lower cost to patients. Sample: 72 patients (36 patients per group), baseline demographics comparable. DRPs addressed: Dermatologist 4 vs PEC 5. 28-day dermatology-related walk-ins: Dermatologist 3 vs PEC 0. Patient satisfaction: 22/23 PEC patients (96.5%) rated care as very good or excellent. Cost: PEC manpower cost/patient: SGD 13.93, Average PEC consultation fee (after subsidy): SGD 19.94, Average direct cost savings for patients reviewed by PEC vs dermatologist: SGD 14.92 (42.8% reduction in consultation fees).
Conclusion
The pharmacist-run dupilumab monitoring service demonstrated satisfactory clinical outcomes and high patient satisfaction at a lower cost to patients.
Lessons Learnt
The pharmacist-led service can effectively manage drug-related problems and reduce dermatology-related walk-ins while maintaining high patient satisfaction and reducing costs.
Keywords
Dupilumab, Eczema, Pharmacist, Monitoring, Service, Patient Satisfaction, Cost Savings
Innovators' Details
Innovators' Details
Healthcare Cluster(s) | National Healthcare Group |
Organization(s) Involved | National Skin Centre, National Healthcare Group Polyclinics |
Platform(s) | Appropriate & Value-based Care Conference |
Healthcare Professional Group(s) | Pharmacy |
Applicable Specialty or Discipline | Dermatology, Pharmacology |
Project Lead(s) | Huang Xiaoling |
Project Member(s) | Germaine CHUA |
Connect with this contributor!
Huang Xiaoling - xlhuang@nhghealth.com.sg
Project Attachment
894_NSC_AVBC 2025_Impact of a pharmacist-run dupilumab monitoring service.pdf